NO992692L - Nefadozon doseringsform - Google Patents

Nefadozon doseringsform

Info

Publication number
NO992692L
NO992692L NO992692A NO992692A NO992692L NO 992692 L NO992692 L NO 992692L NO 992692 A NO992692 A NO 992692A NO 992692 A NO992692 A NO 992692A NO 992692 L NO992692 L NO 992692L
Authority
NO
Norway
Prior art keywords
nefadozone
dosage form
dosage
nefadozone dosage
Prior art date
Application number
NO992692A
Other languages
English (en)
Norwegian (no)
Other versions
NO992692D0 (no
Inventor
Andrew B Dennis
Peter Timmins
Alison C Hodson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO992692D0 publication Critical patent/NO992692D0/no
Publication of NO992692L publication Critical patent/NO992692L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO992692A 1998-06-05 1999-06-03 Nefadozon doseringsform NO992692L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8821198P 1998-06-05 1998-06-05

Publications (2)

Publication Number Publication Date
NO992692D0 NO992692D0 (no) 1999-06-03
NO992692L true NO992692L (no) 1999-12-06

Family

ID=22210038

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992692A NO992692L (no) 1998-06-05 1999-06-03 Nefadozon doseringsform

Country Status (20)

Country Link
US (1) US6143325A (id)
EP (1) EP0966966A3 (id)
JP (1) JP2000007567A (id)
KR (1) KR20000005930A (id)
CN (1) CN1238181A (id)
AR (1) AR018862A1 (id)
AU (1) AU3319999A (id)
BR (1) BR9901782A (id)
CA (1) CA2273546A1 (id)
CO (1) CO5060477A1 (id)
HU (1) HUP9901830A2 (id)
ID (1) ID23458A (id)
IL (1) IL130022A0 (id)
NO (1) NO992692L (id)
NZ (1) NZ336001A (id)
PE (1) PE20000544A1 (id)
PL (1) PL333524A1 (id)
SG (1) SG77244A1 (id)
UY (1) UY25544A1 (id)
ZA (1) ZA993345B (id)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
EP1428535A1 (en) * 1998-11-02 2004-06-16 ALZA Corporation Controlled delivery of antidepressants
DE69930952T2 (de) * 1998-11-02 2006-08-31 Alza Corp., Mountain View Verfahren und Vorrichtung zur kontrollierten Abgabe pharmazeutischer Mittel sowie Dosierungsform hierfür
WO2002069951A2 (en) * 2001-03-02 2002-09-12 Sepracor Inc. Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
KR20030034171A (ko) 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
DK1404331T3 (da) 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release-formuleringer af oxymorphon
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6407128B1 (en) 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US7714006B1 (en) 2001-12-03 2010-05-11 King Pharmaceuticals Research & Development, Inc. Methods of modifying the bioavailability of metaxalone
US20050256131A1 (en) * 2002-05-24 2005-11-17 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
SI1931346T1 (sl) * 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
ES2620293T3 (es) 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
JP2011140510A (ja) * 2011-03-17 2011-07-21 Biovail Lab Inc 塩酸ブプロピオンの放出調節錠剤
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
JP6184903B2 (ja) * 2014-06-04 2017-08-23 ヴァレアント インターナショナル バミューダＶａｌｅａｎｔ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｂｅｒｍｕｄａ 塩酸ブプロピオン放出調節錠剤
JP6078514B2 (ja) * 2014-10-30 2017-02-08 コリア ユナイテッド ファーム，インク 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
CA2233280A1 (en) * 1995-09-29 1997-04-03 Peter Rothbart Sustained release delivery system and long acting narcotic analgesics and antagonists
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form

Also Published As

Publication number Publication date
US6143325A (en) 2000-11-07
BR9901782A (pt) 2000-05-09
IL130022A0 (en) 2000-02-29
JP2000007567A (ja) 2000-01-11
PE20000544A1 (es) 2000-06-29
CN1238181A (zh) 1999-12-15
KR20000005930A (ko) 2000-01-25
SG77244A1 (en) 2000-12-19
AU3319999A (en) 1999-12-16
ZA993345B (en) 2000-08-22
UY25544A1 (es) 2001-08-27
CO5060477A1 (es) 2001-07-30
EP0966966A3 (en) 2000-02-09
AR018862A1 (es) 2001-12-12
CA2273546A1 (en) 1999-10-10
NZ336001A (en) 2000-09-29
ID23458A (id) 2000-04-27
PL333524A1 (en) 1999-12-06
EP0966966A2 (en) 1999-12-29
NO992692D0 (no) 1999-06-03
HUP9901830A2 (hu) 2001-06-28
HU9901830D0 (en) 1999-07-28

Similar Documents

Publication Publication Date Title
DE69834019D1 (de) Dose
NO20003640D0 (no) Ny doseringsform
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
NO992692D0 (no) Nefadozon doseringsform
DE69928777D1 (de) Dosierspender
NO20005913L (no) Legemiddelsammensetning
ID27415A (id) Komposisi farmaseutik
DE69829040D1 (de) Elektroplattierungschemie
DE59914158D1 (de) Metallocenmonohalogenide
DE59911453D1 (de) Aktivkohlefilter
DE69909757D1 (de) Ethylencopolymerisationsverfahren
DE59912371D1 (de) Gleitschalungsfertiger
DE69930866D1 (de) Dosiervorrichtung
DE59901560D1 (de) Retrograder tibianagel
DE69933073D1 (de) Informationsaufzeichnungsträgercassette
ID29262A (id) Komposisi farmasi
DE59911683D1 (de) Fahrzeugschliessanlage
ID27201A (id) Komposisi farmasi
DE69811890D1 (de) Einzellenkalorimeter
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59908968D1 (de) Benzoylpyridazine
DE59913393D1 (de) Fadenchangierung
DE69827358D1 (de) Weglenkungsverfahren
FR2782671B3 (fr) Livre
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application